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ABSTRACT Environmental exposure to Bisphenol A (BPA) has been associated with a 14 
range of adverse health effects, including on the cardiovascular system in humans. Lack 15 
of agreement on its mechanism(s) of action likely stem from comparisons between in vivo 16 
and in vitro test systems and potential multiple effects pathways. In rodents, in vivo, 17 
metabolic activation of BPA produces 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene 18 
(MBP), which is reported to be up to 1000 times more potent as an estrogen than BPA. 19 
We investigated the estrogenic effects and estrogen receptor signaling pathway(s) of BPA 20 
and MBP following early life exposure using a transgenic, estrogen responsive (ERE-21 
TG) zebrafish and a targeted morpholino approach to knockdown the three fish estrogen 22 
receptor (ER) subtypes. The functional consequences of BPA exposure on the 23 
cardiovascular system of zebrafish larvae were also examined. The heart atrioventricular 24 
valves and the bulbus arteriosus were primary target tissues for both BPA and MBP in 25 
the ERE-TG zebrafish, and MBP was approximately 1000-fold more potent than BPA as 26 
an estrogen in these tissues. Estrogen receptor knockdown with morpholinos indicated 27 
that the estrogenic responses in the heart for both BPA and MBP were mediated via an 28 
estrogen receptor 1 (esr1) dependent pathway. At the highest BPA concentration tested 29 
(2500 µg/L), alterations in the atrial:ventricular beat ratio indicated a functional impact 30 
on the heart of 5 days post fertilization (dpf) larvae, and there was also a significantly 31 
reduced heart rate in these larvae at 14 dpf. Our findings indicate that some of the reported 32 
adverse effects on heart function associated with BPA exposure (in mammals) may act 33 
through an estrogenic mechanism, but that fish are unlikely to be susceptible to adverse 34 
effects on heart development for environmentally relevant exposures. 35 
  36 
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INTRODUCTION 37 
Bisphenol A (BPA) was originally developed as a synthetic estrogen1 but has 38 
subsequently been used as a monomer for the production of plastics and resins. These 39 
materials are used in a wide range of consumer products, including plastic drink bottles, 40 
food and beverage can linings and thermal paper2. BPA can leach from these materials 41 
and is taken up into the human body either via dermal contact or ingestion via the gut. 42 
BPA enters aquatic environments predominantly through effluent discharge from 43 
wastewater treatment plants but also directly from manufacturing plants, landfill leachate, 44 
and degradation of plastic litter3. Concentrations of BPA in the aquatic environment are 45 
generally below 1 µg/L, but have been reported up to 21 µg/L in river water and as high 46 
as 17 200 µg/L in landfill leachate4.  47 
BPA binds to and activates estrogen receptors (ERs), mimicking the actions of the 48 
endogenous estrogen 17β-estradiol. Adverse health effects attributed to BPA exposure in 49 
mammals include decreases in sperm production and fertility5, polycystic ovarian 50 
syndrome6, obesity and diabetes7 and cancer8. Epidemiological data indicate positive 51 
correlations between BPA exposure in human populations and various risk factors 52 
pertaining to cardiovascular disease9-12 although BPA has not been proven to be the 53 
causative factor. Human health concerns relating to BPA exposure have led to its ban 54 
from infant feeding bottles in Europe and America13, 14 and its listing as a Substance of 55 
Very High Concern (SVHC) under REACH in 201715. In 2020, BPA will also be banned 56 
in thermal paper in Europe16. 57 
Several experimental studies have reported effects of BPA on the cardiovascular system 58 
in rodents, in vitro cell lines and ex vivo hearts. Lifelong exposure to BPA (0.5 – 5 59 
mg/kg/day) in mice was shown to modify cardiac structure and function with sex specific 60 
effects17. In males there was concentric re-modelling, whereas in females there were 61 
4 
 
increases in systolic and diastolic blood pressure. Further female specific effects reported 62 
include arrhythmia which was exacerbated in the presence of 17β-estradiol18, 19. This 63 
arrhythmic effect was abolished when animals were treated with an ER antagonist, 64 
suggesting mediation via ER signaling18. BPA has also been shown to decrease atrial 65 
contraction rate and force in ex vivo rat hearts at exposure concentrations of 0.23 and 23 66 
mg/L20. 67 
Studies in mammals have also shown that BPA can affect cardiac electrophysiology. 68 
Acute exposure to BPA was shown to decrease ventricular conduction velocity and 69 
increase action potential duration in female hearts21, however, the underlying mechanism 70 
for these effects was not explored.  71 
The molecular mechanisms for BPA effects in the heart in general are not well 72 
established. BPA has been demonstrated to act through a variety of different mechanisms 73 
including via the nuclear estrogen receptors ERα and ERβ (three isoforms exist in fish 74 
esr1 (ERα), esr2a (ERβ2) and esr2b (ERβ1))22, 23 and the orphan receptor Estrogen 75 
Related Receptor γ (ERRγ). BPA activates the ERRγ receptor more effectively than 17β-76 
estradiol24. 77 
Estrogen receptors occur in a wide range of body tissues but the abundance of different 78 
isoforms varies, which can affect the cell sensitivity to a particular ligand25. In 79 
mammalian models, moderate to high-level expression of ERα occurs in the uterus, testis, 80 
pituitary, ovary, kidney and epididymis, while high expression for ERβ occurs in prostate, 81 
ovary, lung, bladder, brain, uterus and testis26. Both ER subtypes occur in the rodent heart 82 
and in human cardiomyocytes25, 27. In fish ER subtype localisation in body tissues also 83 
varies. In the fathead minnow (Pimephales promelas) every ER isoform is expressed in 84 
the brain, pituitary, liver, gonad, intestine, and gill. In the liver esr1 and esr2b are 85 
predominantly expressed, while esr2a is expressed principally in the intestine28. Zebrafish 86 
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embryos at 5 days post-fertilisation (dpf) have been shown to express esr1 transcripts in 87 
the heart while esr2a (reported as esr2b) transcripts appear to be expressed in the liver29. 88 
To add to this complexity, expression of the ER subtypes can also vary during ontogeny 89 
in fish30. 90 
Findings for responses to BPA in vivo are not always supported by in vitro studies. A 91 
possible explanation for this in mammals is that metabolic activation of BPA in vivo 92 
produces 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) which is a more potent 93 
estrogen than BPA31. Metabolic activation may also help to explain non-monotonic 94 
responses that are sometimes observed following BPA exposure32. Incubation of BPA 95 
with S9 liver fractions from mouse, monkey or humans all produce metabolites more 96 
potent as estrogens than the parent BPA compound which are also thought to be MBP31. 97 
In rats and medaka (Oryzias latipes) estrogenic effects of MBP in vivo are between 400 - 98 
1000 times greater than for BPA33-36. Three-dimensional modelling of human ERs 99 
together with binding strength assessments for BPA, MBP and 17β-estradiol suggest that 100 
structural differences account for the increased effectiveness of MBP over BPA37. Despite 101 
these findings MBP has not yet been measured as a natural in vivo metabolite in any 102 
environmental samples. There is little information on the metabolism of BPA to MBP or 103 
otherwise in vivo in fish, but one report indicates an inability to produce the conjugated 104 
metabolite bisphenol A glucuronic acid (BPA-GA) in juvenile trout38. 105 
In this study we investigated the estrogenic responses and estrogen receptor signaling 106 
mechanisms by which BPA and its metabolite in mammals MBP act in an estrogenic 107 
responsive transgenic zebrafish. Estrogen Response Element (ERE)-TG zebrafish were 108 
exposed to estrogenic chemicals in combination with injected morpholino antisense 109 
oligomers i specific to three individual ER subtypes to knockdown function. Responses 110 
to the potent steroidal estrogen 17α-ethinylestradiol (EE2)  in the ERE-TG zebrafish were 111 
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used as a positive control for estrogenic activation. We further assessed whether effects 112 
on heart function in juvenile fish may result from early life developmental exposure to 113 
BPA. 114 
  115 
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MATERIALS AND METHODS 116 
Fish source, culture and husbandry.  All zebrafish embryos used in this study were 117 
obtained from Tg(ERE:Gal4ff)(UAS:GFP) transgenic zebrafish adults39. Full details of 118 
fish husbandry can be found in the Supporting Information. 119 
Chemical preparations. Bisphenol A (purity >99%) and 17α-Ethinylestradiol (≥98%) 120 
(EE2) were purchased from Sigma-Aldrich Company Ltd. (Gillingham, UK). 4-methyl-121 
2,4-bis(4-hydroxyphenol)pent-1-ene (MBP) was synthesized at the University of Exeter 122 
as described by Cipelli et al40. Stock chemicals were prepared as described previously by 123 
Moreman et al41. 124 
 125 
Tissue responses to chemical treatments. All exposures were conducted in a 126 
temperature controlled laboratory held at 28 ± 1 oC, in glass vessels with daily renewal 127 
of the media. To determine tissue differences in response to BPA, MBP and EE2, embryos 128 
were exposed to these chemicals at a series of different concentrations or to solvent 129 
control. BPA and MBP have similar molecular weights (228.3 g and 268.4 g respectively) 130 
and effects comparisons are made on a w/v basis: 100 µg/L = approx. 0.4 µM for both 131 
materials). Concentration ranges based on preliminary investigations for EE2 were 2.0 132 
and 20 ng/L, for BPA 10, 100 and 1000 µg/L, and for MBP 0.025, 0.25 and 2.5 µg/L. 133 
Each experimental group consisted of 20 embryos exposed in 100 mL of ISO water and 134 
each treatment group was run in triplicate. The exposures were conducted from 0 hpf to 135 
120 hpf. At the end of the exposure period, 120 hpf old larvae were processed for 136 
fluorescent imaging analysis. 137 
To investigate responses to BPA and MBP specifically in the heart of developing 138 
zebrafish a similar exposure regime as described above was used but across a narrower 139 
chemical exposure range. To better visualise the location of GFP expression in the heart, 140 
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larvae were stained with MF-20 monoclonal antibody, which stains cardiac myosin, and 141 
hearts were then excised from stained larvae for imaging. Full details of the 142 
immunostaining technique can be found in the Supporting Information. 143 
Morpholino analysis and injection. Morpholino (MO) design is described in the 144 
Supporting Information. Using a microinjector (INTRACEL, PICOSPRITZER®III) 2nL 145 
of 0.25 mM MO solution was injected into the yolk proximal to the blastomeres of the 146 
embryo at the one- to four-cell stage, control embryos were injected with 2 nL of solution 147 
containing no MO. Fluorescence imaging of MO injected and chemically exposed larvae 148 
was conducted at 72 hpf as pilot studies demonstrated that for a combination of all three 149 
esr morpholinos the maximum inhibitory effect occurred up to 72 hpf. 150 
Image analysis of Tg(ERE:Gal4ff)(UAS:GFP) zebrafish. All larval images were 151 
obtained using a Zeiss Axio Observer.Z1 equipped with an AxioCam Mrm camera (Zeiss, 152 
Cambridge, UK) as described in the Supporting Information.  153 
Confocal microscopy was used on stained dissected hearts. The hearts were mounted 154 
in 0.7 % agarose (low melting point). Hearts were photographed under X20 magnification 155 
on a confocal-laser scanning microscope (ZEISS LSM510). Images were reconstituted 156 
using LSM510 Meta. 157 
Cardiovascular functional analysis. To assess for effects on heart function and blood 158 
flow, non-invasive video analysis of the heart and dorsal aorta was used to measure 159 
multiple cardiovascular endpoints; including beat rate, atrial:ventricular beat ratio, blood 160 
flow/velocity, stroke volume and blood vessel diameter42. Studies were conducted on fish 161 
at 5 dpf and 14 dpf following exposures to both 1000 µg/L BPA, and 2500 µg/L BPA.  162 
Following chemical exposure, two cameras captured separate videos of larvae to 163 
measure the cardiovascular endpoints. One camera (Grasshopper® GRAS-50S5C-C, 164 
Point Grey, Richmond, Canada) was positioned to capture the whole heart at 30 frames 165 
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per second (fps) and the second (Grasshopper® GRAS-03K2M-C, Point Grey, 166 
Richmond, Canada) to capture the dorsal aorta, caudal to the swim bladder, at 120 fps. 167 
Videos were analysed using MicroZebraLab™ (v3.5, ViewPoint, Lyon, France) or 168 
ZebraBlood™ (v1.3.2, ViewPoint, Lyon, France) software. Full details of cardiovascular 169 
functional analysis are provided in the Supporting Information. 170 
Measured chemical exposure concentrations. For water samples measured 171 
concentrations were determined for 1000 µg/L BPA and 0.25, 2.5 and 25 µg/L MBP using 172 
LC-MS/MS analysis. . For uptake analysis embryo-larvae were exposed to 1000 µg/L 173 
BPA and 0.25, 2.5 and 25 µg/L MBP. See Supporting Information for full details on 174 
chemical analysis and larval preparation.  175 
Data analysis. Fluorescence data are expressed as mean fold induction above the 176 
solvent control, ± standard error of the mean (SEM). Data quoted in the text, or shown 177 
graphically, for cardiac function parameters are presented as the mean ± SEM over the 5 178 
minute observation period. Data for A:V beat ratio at 5 dpf were separated into 0.5 minute 179 
time segments to clearly visualise observed fluctuations in A:V ratio in exposure groups. 180 
Significant differences between groups were analysed using a one-way ANOVA, and a 181 
Tukey posthoc test was carried out where significant differences were detected (p < 0.05). 182 
A Kolmogorov-Smirnov test was used to compare the distribution curves between 183 
treatments for A:V beat rate data and differences were reported as significant at p < 0.05. 184 
Statistical analyses of data were performed in IBM SPSS Statistics 22. 185 
  186 
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RESULTS 187 
Uptake and metabolism of BPA in exposed embryos. Accurate dosing of test 188 
chemicals was confirmed at the start of the exposures (Supporting Information Table S2). 189 
At a concentration of 0.25 µg/L, MBP was below the limit of quantification (LOQ) of the 190 
analytical method (0.4 µg/L). Larvae exposed to BPA at a concentration of 1000 µg/L 191 
resulted in an internal BPA load of 2.3 ± 0.2 ng/larvae (Table S2), equating to an 192 
estimated bioconcentration factor (BCF) of 2.3 (assuming a larval volume of 1 µL). MBP 193 
was not detected in 5 dpf zebrafish embryos exposed to BPA. Similarly, MBP was not 194 
detected in larvae exposed to 0.25 µg/L MBP and 2.5 µg/L MBP with LC-MS analysis. 195 
MBP was, however, detected in larvae exposed to the highest MBP concentration (25 196 
µg/L) with an internal MBP concentration of 0.66 ± 0.16 ng/ larvae equating to a BCF of 197 
26.4. 198 
Tissue expression of GFP in response to BPA, MBP and EE2 in ERE-TG zebrafish 199 
larvae. Some ERE-TG zebrafish had detectable GFP expression in the otic vesicle in the 200 
absence of chemical treatment (Figure 1A). This fluorescence was not inducible by the 201 
chemicals tested and had a similar level of occurrence across all treatments. No GFP 202 
fluorescence was detected in other tissues of control larvae.  203 
For exposure to EE2 the most responsive tissue was the liver; an exposure concentration 204 
of 2 ng/L resulting in an 8.6 ± 2.1- fold increase in GFP fluorescence above controls. At 205 
20 ng µg/L EE2, increased fluorescence was detected in the heart (9.6 ± 0.9-fold 206 
increase), liver (128 ± 16-fold increase) and muscle somites in tail region (13.2 ± 0.6-fold 207 
increase). Responses to EE2 were much more pronounced in liver and muscle somites 208 
compared with in the heart. 209 
Responses to the phenolic compounds differed compared with that for EE2.  No 210 
induction of GFP was detected in ERE-TG zebrafish exposed to 10 µg/L BPA (Figure 1), 211 
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but there was a significant increase in GFP fluorescence in the heart at 100 µg/L BPA 212 
(3.2 ± 0.7-fold above control) (Figure 1B), but not in other tissues (Figure 1C and D).  In 213 
larvae exposed to 1000 µg/L BPA a GFP fluorescence signal was detected in the heart, 214 
liver and muscles somites in the tail region (Figure 1B - D), with fold increases above 215 
control of 25.7 ± 2.0, 55.6 ± 5.5 and 10.4 ± 1.8, respectively. Fluorescence in the tail 216 
region was associated with individual muscle myotubes, expressed in a mosaic pattern, 217 
and in the corpuscles of Stannius (Figure 1A). 218 
Exposure to MBP resulted in a very similar pattern of fluorescence expression to that 219 
for BPA, but MBP produced a stronger response. A response in the heart was detected at 220 
an MBP exposure concentration of 0.25 µg/L (3.5 ± 0.6 -fold increase above control) 221 
increasing to 32.6 ± 1.6-fold above controls at 2.5 µg/L. At 2.5 µg/L MBP fluorescence 222 
was also detected in the liver and tail regions at 78.4 ± 13.1 and 12.1 ± 0.9-fold above the 223 
controls, respectively. 224 
Heart valves responses to BPA and MBP.  Examples of hearts from larval zebrafish 225 
exposed to BPA and MBP and stained with MF-20 (to identify myocardium tissue) for 226 
microscopy analysis are shown in Figure 2. The main GFP expression domains within the 227 
heart were the atrioventricular valve and the bulbus arteriosus, structural features that are 228 
essential for regulating blood flow in fish. At the higher exposure concentrations used 229 
(1000 µg/L BPA and 2.5 µg/L MBP) GFP fluorescence was seen to extend from the 230 
atrioventricular value throughout the ventricular tissue. There was no evidence that the 231 
overall morphology of valves or bulbus arteriosus were affected by the chemical 232 
treatments. 233 
Concentration dependent responses for GFP fluorescence induction in the heart were 234 
observed for both BPA and MBP. Equivalent fold-increases in fluorescence above control 235 
for BPA and MBP occurred at 1000 µg/L (23.6 ± 2.6 fold) and 1 µg/L (23.4 ± 3.5 fold) 236 
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respectively, indicating MBP (based on GFP fluorescence intensity) had a relative 237 
potency 1000 times greater than BPA for responses in the heart valves. 238 
Estrogen Receptor signaling pathways for BPA and MBP in ERE-TG zebrafish. 239 
To determine which ERs were responsible for the observed tissue specific responses, 240 
ERE-TG zebrafish larvae were injected with antisense morpholinos for the different ER 241 
subtypes and subsequently treated with BPA, MBP or EE2.  242 
Negative-morpholino control fish exposed to BPA (1000 µg/L), MBP (2.5 µg/L) and 243 
EE2 (20 ng/L) showed significant increases in GFP fluorescence intensity in the heart, 244 
liver, anterior trunk and tail regions (Figure 3). Injection with the morpholino for esr1, 245 
resulted in a suppression of GFP signal in the heart, liver and somite muscles in the trunk 246 
region of the body (Figure 3B-D). GFP fluorescence intensity in esr1-MO injected fish 247 
was reduced for all chemical exposures in the heart and liver to levels that did not differ 248 
from controls (i.e. complete suppression of the GFP) (Figure 3B, 3C). GFP fluorescence 249 
intensity in esr1-MO injected embryo was reduced in the trunk region in fish exposed to 250 
BPA. Although reduced compared to the negative morpholino control, the esr 1 morphant 251 
fish exposed to MBP and EE2 still demonstrated significantly higher fluorescence than 252 
unexposed fish (Figure 3D). 253 
In contrast, zebrafish injected with morpholinos for esr2a and esr2b continued to exhibit 254 
increased GFP fluorescence in the heart when exposed to the estrogenic chemicals. There 255 
was no significant increase observed in GFP fluorescence for BPA, MBP and EE2 esr2a 256 
& esr2b exposed morphants in the liver, trunk, and tail regions when compared to the 257 
controls (Figure 3 C-E). This indicates that a combined knockdown of esr2a and esr2b 258 
may prevent estrogen signaling in these tissues. 259 
Effects of BPA on heart function in 5 and 14 dpf zebrafish. For 5 dpf fish GFP 260 
fluorescence intensity in the heart was 8.9 ± 1.2-fold above controls for 1000 µg/L BPA, 261 
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and 10.8 ± 1.4-fold above controls for 2500 µg/L BPA; and for the 14 dpf fish, 50.7 ± 262 
11.5-fold above controls for 1000 µg/L BPA and 44.7 ± 7.7-fold above controls for 2500 263 
µg/L BPA (Figure 4). 264 
At 5 dpf, there were no significant effects for either of the two BPA exposure 265 
concentrations on heart beat rate, dorsal aorta diameter, the speed or volume of blood 266 
flow or the surrogate stroke volume. No significant differences were found between the 267 
means of the atrium to ventricle (A:V) beat ratio values (data not shown). Comparing the 268 
distribution pattern around the means (using a Kolmogorov-Smirnov analysis) showed 269 
that in the 2500 µg/L BPA treatment group there was a significantly different pattern in 270 
the frequency of the heart beat from the control and 1000 µg/L BPA treatment group. 271 
When the A:V beat ratio measurements were divided into 30 second time bins 272 
representing means +/-SEMs (Figure 4E) for those time intervals, the variation in beat 273 
ratio was be greater for the higher BPA treatment compared with controls, (p < 0.05, 274 
Kolmogorov-Smirnov test), varying more across the 30 second time intervals indicating 275 
a more erratic A:V beat ratio for those fish. 276 
Pigment formation at 14 days precluded accurate detection of atrial and ventricular beat 277 
rates due to an inability to clearly visualise the heart. Heart beat rate, however, was 278 
estimated from the pulse rate of the dorsal aorta. There was no effect of BPA exposure 279 
on volume or speed of blood flow, dorsal aorta diameter, or surrogate stroke volume. 280 
However, there was a significant reduction in the arterial beat rate of fish exposed to 2500 281 
µg/L BPA (184 ± 3.5 bpm compared with 201 ± 4.6 bpm in controls, p < 0.05,  Figure 282 
4D).  283 
  284 
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DISCUSSION 285 
Estrogens have widespread effects including in the heart. Estrogen effects on 286 
circulatory function, mediated through genomic and non-genomic mechanisms, are well 287 
documented43, leading to suggestions that BPA and other xenoestrogens may exert 288 
adverse effects on the cardiovascular system. Several epidemiological studies have 289 
reported that BPA exposure in humans is associated with an increased occurrence of 290 
cardiovascular disease9-12, however, there is little direct experimental evidence to support 291 
this, and the mechanisms by which this may occur are not known. The zebrafish heart 292 
differs structurally in some aspects from the mammalian heart but the molecular 293 
mechanisms underlying cardiac development and function are highly conserved between 294 
mammals and fish, and with phenotypic similarities between cardiac mutants in fish and 295 
human diseases also, the zebrafish model has become widely used in cardiac research44. 296 
Here we used an ERE-TG zebrafish, in combination with morpholino knockdown of ER 297 
subtypes, to identify potential signaling mechanisms for BPA and its metabolite MBP in 298 
the heart and across other body tissues, and assessed for effects of early life exposure to 299 
BPA on subsequent heart function.  300 
Estrogenic responses to BPA occurred in the heart, liver, muscle somites and corpuscles 301 
of Stannius, as identified previously in different lines of estrogen responsive transgenic 302 
zebrafish29, 39. In the heart, the atrioventricular valves and bulbus arteriosus were most 303 
responsive to BPA exposure (Figure 2). MBP showed similar spatial patterns of ER 304 
activation, as indicated by increased GFP-fluorescence in the ERE-TG zebrafish, 305 
including for the heart valves and bulbus arteriosus, but with apparent higher potency. 306 
Across the different body tissues, MBP was between 400 - 1000 times more potent than 307 
BPA, which is consistent with findings reported for relative estrogenic potencies in 308 
mammals in vivo33-36. For the heart, the threshold concentration for induction of 309 
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measurable GFP fluorescence was 100 µg/L for BPA, compared with 0.25 µg/L for MBP. 310 
It is possible that some effects for BPA in the ERE-TG zebrafish derived from its in vivo 311 
metabolism to MBP, however we did not detect MBP in 5 dpf zebrafish exposed to BPA, 312 
even at 1000 µg/L. This may indicate that zebrafish larvae do not possess the effective 313 
liver function to metabolise BPA to MBP, or that the level of MBP in these larvae was 314 
below the detection limit for our analysis method (0.4 µg/L).  MBP was detectable in 315 
larvae on exposure to the highest concentration of MBP tested (25 µg/L).  316 
Induction of GFP by both BPA and MBP was inhibited in the hearts of ERE-TG larvae 317 
injected with morpholinos against esr1 (Figure 3). In liver, morpholinos against esr1 and 318 
against esr2a and esr2b together inhibited GFP expression, whereas in the somite 319 
myotubes (most notably in the tail region) the combined esr2a and esr2b morpholinos 320 
were effective, but the esr1 morpholino was not. These data indicate that different ER 321 
response pathways occur for the bisphenols within different body tissues. Studies on a 322 
zebrafish liver cell line, transfected with different ERs found that BPA most strongly 323 
activated ERα (esr1), with some activation of ERβ2 (esr2a) and no detectable effect on 324 
ERβ1 (esr2b)45. It is possible that the preferences indicated for different ERs could lead 325 
to different chemicals targeting specific tissues, resulting in the differing response 326 
patterns observed. Studies in vitro in mammalian-based systems including human ERα 327 
and rat ERβ protein synthesized in reticulocyte lysates41 and rat liver S9 liver fractions, 328 
indicate that BPA preferentially binds to and activates ERβ but this has not been 329 
confirmed in vivo.   330 
Whole mount in situ hybridisation conducted in 5 dpf zebrafish has shown the presence 331 
of  esr1 transcripts in the atrioventricular valves and bulbus arteriosus and esr2a (reported 332 
as esr2b) transcripts in the liver29. In that study, esr2b (reported as esr2a) transcripts were 333 
not detected29. This suggests that esr1 plays an important functional role in transducing 334 
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the estrogenic signal in the cardiac tissue during early life. This may explain why 335 
estrogenic chemicals, such as BPA, with a higher affinity for esr1, show activation 336 
responses in the heart at concentrations lower than those seen in other tissues. In our study 337 
the GFP signal in the liver was knocked down using the esr1 morpholino (as well as the 338 
morpholinos for esr2a and esr2b) indicating hepatic expression of esr1 transcripts, which 339 
contrasts with studies reported for another transgenic zebrafish line for the same life 340 
stage29. It is well estabslished, however, that esr1 is expressed in the liver in many fish 341 
species (including the zebrafish) at later life stages, where it plays a role in regulating the 342 
expression of estrogen responsive genes, including signaling pathways for induction of 343 
vitellogenin46. Cross-talk between the esr sub-types is likely to occur in the liver (and 344 
other body tissues) and there may be involvement of other factors in estrogen signaling, 345 
that lead to a reduced GFP signal when either receptor subtype is knocked down/out. 346 
Both BPA and MBP targeted the atrioventricular valves and bulbus arteriosus, tissues 347 
responsible for regulating blood flow from early life. The valves of the atrioventricular 348 
canal are crucial for maintaining unidirectional blood flow in the heart, completely 349 
blocking retrograde blood flow by 72 hpf47 with the valve leaflets developed by 102 hpf48. 350 
The bulbus arteriosus functions as a type of capacitor to maintain a continuous blood 351 
flow. The first five days of life are crucial for correct valve development in zebrafish with 352 
the valves forming from migrating endocardial cells at this time49. In humans, it has been 353 
estimated that 5% of children may carry some form of congenital valve deformation, and 354 
10 - 20% of all congenital heart disease is caused by defects in the atrioventricular canal50, 355 
51. This emphasises the need to establish whether chemicals, such as BPA, known to act 356 
on these tissues during development, effect valve function contributing to congenital heart 357 
disease, and to establish the mechanisms for any such effects. 358 
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Non-invasive video analysis has previously been used in the assessment of integrated 359 
cardiovascular function following drug treatment in zebrafish42. Endocardial cushion 360 
(precursors to functioning valves) development is thought to be complete around 5 dpf 361 
while valve elongation is thought to occur from around 6 dfp, completing at around 14 362 
dpf48. If BPA significantly impacts heart valve function in zebrafish larvae, effects should 363 
therefore be detectable at this time. At 5 dpf the only significant effect measured was the 364 
difference in A:V beat ratio. This ratio was relatively conserved at 1:1 in control larvae 365 
with little variation observed throughout the 5 minute observation window. In fish 366 
exposed to 2500 µg/L BPA, A:V beat ratio was more variable over the assessment period 367 
(Figure 4E), indicating that although there was no uniform decoupling of atrial and 368 
ventricular beat rates, BPA exposure at high concentrations can cause erratic beat in 369 
either, or both, heart chambers. It is unlikely that A:V beat ratio would be linked to a 370 
disruption of the heart valves, however in dissected hearts fluorescent cells extending into 371 
the ventricle were observed (Figure 2A), possibly indicating BPA action, but more 372 
detailed and higher resolution microscope analyses would be required to develop a better 373 
understanding on this possibility. Previous studies have indicated that BPA may promote 374 
arrhythmia in mammalian hearts by alteration of myocyte Ca2+ handling, mediated by 375 
ERβ-signaling18, 19, 52. Estrogen-responsive fluorescent signaling in our ERE-TG fish 376 
appears to be mediated by an esr1-dependent pathway but at the higher concentration of 377 
2500 µg/L BPA further pathways may also be induced. The only significant effect 378 
observed at 14 dpf was a reduction in heart rate (as indicated using arteria; pulse data) in 379 
zebrafish exposed to 2500 µg/L BPA although the mechanism for this was not 380 
determined. BPA, however, has been shown to affect thyroid signaling53 and reduced 381 
circulating thyroid hormones can lead to a reduction in heart rate in humans54.  382 
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In conclusion, we demonstrate that the estrogenic BPA metabolite MBP targets the 383 
same tissues as its parent compound, BPA, and distinct from that of the pharmaceutical 384 
steroidal estrogen EE2. In common with data from mammals, the potency of MBP in the 385 
zebrafish is several orders of magnitude higher than for BPA. We demonstrate that 386 
developing atrioventricular valves and bulbus arteriosus are key targets in the heart for 387 
both BPA and MBP and the estrogenic signal transduction for both bisphenols are 388 
mediated via an esr1 dependent pathway. Although we show the potential for ER- 389 
mediated mechanisms to account for the reported cardiovascular effects in humans for 390 
these bisphenols, for fish functional effect concentrations for early life stage exposure far 391 
exceed those for most environments by several orders of magnitude. From these data it 392 
seems unlikely that chronic exposure to BPA and MBP in natural environment will have 393 
functional consequences for the heart in fish.  394 
  395 
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 396 
Figure 1. Tissue responses in ERE-TG zebrafish larvae exposed to BPA and MBP. (A) 397 
Representative images of 120 hpf ERE-TG zebrafish larvae for controls and exposures to 398 
1000 µg/L BPA, 2.5 µg/L MBP and 20 ng µg/L EE2 (images for lower exposure 399 
concentrations are not shown; OV=otic vesicle, H=heart, SM=somite muscle, L=liver). 400 
(B-D) GFP induction in 120 hpf ERE-TG zebrafish larvae exposed to BPA and MBP 401 
(concentrations indicated in µg/L) and EE2 (concentrations in ng/L). Data presented as 402 
fold-increase above controls for the (B) heart, (C) liver, (D) tail somites.  Letters represent 403 
significant differences (p < 0.05) between the chemical treatment and control groups.  404 
 405 
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 406 
Figure 2. Composite z stacks of hearts dissected from 120 hfp ERE-TG zebrafish larvae 407 
exposed to a gradient of concentrations of (A) BPA and (B) MBP (A=atrium, 408 
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V=ventricle, AV=atrioventricular valve, BA=bulbus arteriosus. Hearts were 409 
immunostained with MF-20 to identify cardiac tissue. GFP induction (fluorescence 410 
intensity) was measured and quantified using fluorescence microscopy and image 411 
analysis, (C) BPA and (D) MBP exposures Letters represent significant differences (p < 412 
0.05) between the chemically dosed and control groups.  413 
  414 
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 415 
 416 
Figure 3. Effects of ER morpholino knockdowns on ERE-TG zebrafish larvae exposed 417 
to BPA and MBP. (A) Images of ERE-TG zebrafish larvae at 72 hpf for controls and 418 
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larvae exposed to 1000 µg/L BPA, 2.5 µg/L MBP and 20 ng µg/L EE2 injected with 419 
morpholinos against esr1, or esr2a & esr2b at 1-4 cell stage to knockdown the specific 420 
ERs (H=heart, L=liver, SM=somite muscle; numerical values represent differing 421 
exposure times across different regions due to present levels of fluorescence). (B-E) 422 
Fluorescence response in 72 hpf ERE-TG zebrafish larvae exposed to BPA, MBP and 423 
EE2 in combination with the injected morpholinos against esr1 or esr2a & esr2b 424 
expressed as fold increase above controls for target tissues; (B) heart, (C) liver, (D) 425 
muscle somites in the trunk region, and (E) muscle somites in the tail region. Letters 426 
represent significant differences (p < 0.05) between the chemically dosed and control 427 
groups. 428 
 429 
  430 
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 431 
 432 
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Figure 4. Images of hearts in ERE-TG zebrafish exposed to 1000 and 2500 µg/L BPA at 433 
5 dpf and 14 dpf. (A) Heart outline shown on 5 dpf control. GFP induction in hearts of 434 
ERE-TG zebrafish used for analysis of cardiac function at (B) 5 dpf and (C) 14 dpf 435 
measured as fold- increase above controls. (D) Estimated heart rate based on arterial 436 
blood flow at 14 dpf. Letters represent significant differences (p < 0.05) between the 437 
chemically dosed and control groups. (E) Atrial to ventricular beat ratio in 5dpf zebrafish 438 
data split in 30s time segments and shown as means +/- SEMs.  439 
  440 
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